212 related articles for article (PubMed ID: 20697951)
1. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.
Hu XM; Liu F; Ma R
Chin J Integr Med; 2010 Aug; 16(4):368-77. PubMed ID: 20697951
[TBL] [Abstract][Full Text] [Related]
2. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Evens AM; Tallman MS; Gartenhaus RB
Leuk Res; 2004 Sep; 28(9):891-900. PubMed ID: 15234563
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.
Murgo AJ
Oncologist; 2001; 6 Suppl 2():22-8. PubMed ID: 11331437
[TBL] [Abstract][Full Text] [Related]
4. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
[TBL] [Abstract][Full Text] [Related]
8. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
[TBL] [Abstract][Full Text] [Related]
9. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
10. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
11. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
Wang L; Zhou GB; Liu P; Song JH; Liang Y; Yan XJ; Xu F; Wang BS; Mao JH; Shen ZX; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4826-31. PubMed ID: 18344322
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
13. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
[TBL] [Abstract][Full Text] [Related]
14. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
[TBL] [Abstract][Full Text] [Related]
15. Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder () in Patients with Myelodysplastic Syndrome.
Deng ZY; Zhu SR; Wang MJ; Fang S; Zhao P; Zhu QZ; Wang HZ; Guo XQ; Xu YG; Yi BW; Shang XH; Ma R; Hu XM
Chin J Integr Med; 2019 Jul; 25(7):497-501. PubMed ID: 31278627
[TBL] [Abstract][Full Text] [Related]
16. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
18. Expanding the use of arsenic trioxide: leukemias and beyond.
Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
[TBL] [Abstract][Full Text] [Related]
19. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Bonati A; Rizzoli V; Lunghi P
Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
